Elias Jabbour, MD, is actively involved in research in acute and chronic forms of leukemia; and was actively involved in clinical trials that led to the approval of several drugs in chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), and acute lymphoblastic leukemia (ALL). He has assisted in the development of chemotherapeutic and biologic agents in leukemias, and has been involved in addressing the question of genomic instabilities in patients with low-risk MDS who may need earlier therapeutic intervention. This served as a rationale for the first study in the world randomizing such patients to either 5-azacitidine or decitabine. Dr. Jabbour has participated in numerous scientific meetings, authored or co-authored more than 400 peer-reviewed publications and abstracts, and serves as a reviewer for many scientific journals.
Dr. Jabbour is a recipient of several prestigious awards, among them merit awards from the American Society of Clinical Oncology and the American Society of Hematology. He also received several honors, including the Kimberly Patterson and Shannon Timmins fellowships, the 2007 Celgene Future Leader in Hematology Award, and the 2016 Young Investigator in Hematology Award.